CCT6A and gastric cancer: CCT6A expression in GC tumor tissues was associated with resistance to CGP60474 and SB52334, and sensitivity to camptothecin, TGX221, talazopanib, etoposide, gemcitabine, HG511301, TW37, vinorelbine, and gefitinib (Figure 10H).